Dulaglutide, a long-acting GLP-1 receptor agonist, can suppress copeptin levels in individuals with euvolaemia, a secondary ...
Please provide your email address to receive an email when new articles are posted on . Tirzepatide had similar effects to dulaglutide on most heart outcomes regardless of heart failure status.
HOUSTON — The dual GLP-1/GIP receptor agonist tirzepatide showed significantly greater efficacy than the GLP-1 dulaglutide in the treatment of major kidney outcomes in patients with type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results